

Key variable set (similar to the International Sarcoma Registry [ISR] Minimal Dataset [MDS])		
Variable	Label	Value
Age at diagnosis	In years	Number (0 – X)
Sex	Female	0
	Male	1
Primary sarcoma	No	0
	Yes	1
Tumour side	Left	0
	Right	1
	Midline	2
Tumour location	Upper extremity	
	Axilla	0
	Shoulder	1
	Arm	2
	Elbow	3
	Forearm	4
	Wrist	5
	Hand	6
	Lower extremity	
	Gluteal	7
	Pelvis	8
	Thigh	9
	Knee	10
	Popliteal fossa	11
	Leg	12
	Ankle	13
	Foot	14
	Axial	
	Trunk	15
	Flank	16
	Paraspinal	17
Longitudinal location	Proximal	0
	Midshaft	1
	Distal	2
	Not applicable	3
Tumour histology	Fibrosarcoma	
	Myxofibrosarcoma	1
	Solitary fibrous tumour (SFT)	2
	Inflammatory myofibroblastic tumour	3
	Fibromyxoid sarcoma	4
	Dermatofibrosarcoma protuberans	5
	Giant cell fibroblastoma	6
	Myofibroblastic sarcoma	7
	Sclerosing epithelioid sarcoma	8
	Liposarcoma	
	ALT/WDLS	9
	Myxoid liposarcoma	10
	Dedifferentiated liposarcoma	11
	Pleomorphic liposarcoma	12
	Uncertain differentiation	
	Extraskeletal osteosarcoma	13
	Extraskeletal myxoid chondrosarcoma	14

Project – 10 000 STS patients

	Epithelioid sarcoma	15
	Alveolar soft part sarcoma	16
	Clear cell sarcoma	17
	Plexiform fibrohistiocytic tumor	18
	Malignant tenosynovial giant cell tumor	19
	Giant cell tumor of soft tissue	20
	Angiomatoid fibrous histiocytoma	21
	Malignant ossifying fibromyxoid tumor	22
	Myoepithelial carcinoma	23
	Hemosiderotic fibrolipomatous tumor	24
	Malignant phosphaturic mesenchymal tumor	25
	Extrarenal rhabdoid tumor	26
	Ewing's sarcoma	27
	Desmoplastic small round cell tumor	28
	Synovial sarcoma	29
	Vascular sarcoma	
	Angiosarcoma	30
	Kaposi sarcoma	31
	Pseudomyogenic hemangioendothelioma	32
	Epithelioid hemangioendothelioma	33
	Leiomyosarcoma	34
	Neural sarcoma	
	Malignant peripheral nerve sheath tumor	35
	Melanotic schwannoma	36
	Malignant perineuroma	37
	Malignant granular cell tumor	38
	Rhabdomyosarcoma	
	Embryonal	39
	Pleomorphic	40
	Alveolar	41
	Spindle cell	42
	Undifferentiated sarcoma	
	Undifferentiated pleomorphic sarcoma	43
	Undifferentiated round cell sarcoma	44
	Undifferentiated spindle cell sarcoma	45
	Undifferentiated epithelioid sarcoma	46
<i>If Tumour histology does not cover the histological subtype</i>	Histological subtype	Free text
Other tumour histology		
Tumour grade	Grade 1	1
	Grade 2	2
	Grade 3	3
	Grade X (non-gradeable histology)	4
Tumour size	< 5 cm	0
	> 5 cm and ≤ 10 cm	1
	> 10 cm and ≤ 15 cm	2
	> 15 cm	3
Tumour depth	Superficial	0
	Deep	1
Presence of DM at presentation	No	0
	Yes	1

Project – 10 000 STS patients

Final margins	Intralesional resection Macroscopic positive (R2) Microscopic positive (R1) Marginal (R0, <1 mm) Wide (R0, >1 mm, no residual tumor)	0 1 2 3 4
Type of surgery	Limb salvage Amputation	0 1
CTX (use of CTX, regardless of timing)	No Yes	0 1
If CTX = Yes (1) Use of preoperative CTX	No Yes	0 1
If CTX = Yes (1): Use of postoperative CTX	No Yes	0 1
RTX (use of RTX, regardless of timing)	No Yes	0 1
If RTX = Yes (1) Use of preoperative RTX	No Yes	0 1
If RTX = Yes (1) Use of postoperative RTX	No Yes	0 1
If RTX = Yes (1) Use of intraoperative RTX	No Yes	0 1
If RTX = Yes (1) Use of definite RTX (no surgery)	No Yes	0 1
Additional variable dataset		
Variable	Label	Value
Country	Of contributing center	Free text
Intitution name	Of contributing center	Free text
Educational level	Primary education (e.g. elementary school) Secondary education (e.g. middle school, junior high-school, senior high school) Academic (university)	1 2 3
Biopsy at referral centre	No Yes	0 1
Type of biopsy (core needle, fine-needle, open)	Core needle biopsy Fine-needle biopsy Open biopsy	0 1 2
MDT meeting	No Yes	0 1

Project – 10 000 STS patients

Bone resection necessary to achieve wide margins	No Yes	0 1
Bony involvement (of primary tumour)	No Yes	0 1
<i>If “Bony involvement” = Yes (1)</i> Type of bone resection	Periosteal stripping Prophylactic nailing/plating Tumour endoprosthesis	0 1 2
Soft tissue involvement (of primary tumour)	No Yes	0 1
<i>If “Soft tissue involvement” = Yes (1)</i> Type of soft tissue reconstruction	None Neurovascular Skin graft Local flaps Free flaps	0 1 2 3 4
<i>If presence of DM at presentation = Yes (1)</i> Location of DM at presentation	Lung Liver Soft tissues Bone Lymph nodes Brain Other	0 1 2 3 4 5
<i>If CTX = Yes (1)</i> Type of CTX	E.g. “ifosfamide”	Free text
<i>If CTX = Yes (1)</i> Number of CTX cycles	Number of cycles	Number (0 – X)
<i>If RTX = Yes (1)</i> Dose of RTX	In Gray (Gy)	Number (0 – X)
Use of isolated limb perfusion (ILP)	No Yes	0 1
Postoperative complications	No Yes	0 1
<i>If postoperative complications = Yes (1)</i> Type of postoperative complication	Wound healing deficit* Infection* Haematoma formation* Dislocation* Deep vein thrombosis Pulmonary embolism Fracture Vascular Neurologic Other <i>*With or without revision surgery</i>	0 1 2 3 4 5 6 7 8 9
If Type of postoperative	Detailed description of other postoperative complication	Free text

Project – 10 000 STS patients

complication = Other (9)		
Description of other postoperative complication		
Local follow-up modality	Ultrasound of affected site CT of the affected site MRI of the affected site	0 1 2
Systemic follow-up modality	Chest x-ray Chest CT-scan* PET-CT scan <i>*with or without abdomen/pelvis</i>	0 1 2
Occurrence of LR	No Yes <i>LR either verified via biopsy or imaging (MRI scan)</i>	0 1
Time to LR	Calculated from date of definite surgery to date of LR <i>Date of LR defined as first clinical or histological verification of LR (e.g. either date of biopsy for LR or date of imaging at which time point locally recurrent tumour disease was apparent)</i>	In months
Occurrence of DM	No Yes <i>DM either verified via biopsy or unequivocal imaging (earlier indeterminate findings [e.g., small nonspecific pulmonary nodules] are not considered metastatic until they show progression or typical features consistent with metastases)</i>	0 1
Time to DM	Calculated from date of definite surgery to date of DM <i>Date of DM either verified via biopsy or unequivocal imaging (earlier indeterminate findings [e.g., small nonspecific pulmonary nodules] are not considered metastatic until they show progression or typical features consistent with metastases)</i>	In months
Follow-up time	Calculated from date of definite surgery to date of last follow-up Date of last follow-up one of the following: 1. Last contact or visit to study center 2. Last telephone contact with study center 3. Last contact with study center	In months
Outcome	Alive without evidence of disease Alive with disease (AWD) Death of disease (DOD)	0 1 2

Project – 10 000 STS patients

	Death of other causes (DoC)	3
	Death of unknown causes	4
	Lost to follow-up	5
Status	Alive	0
	Dead	1
	Lost to follow-up	2
Type of latest functional outcome score	MSTS	0
	TESS	1
<i>If Type of latest functional outcome score = Yes (1)</i>	Percent of total score (for MSTS and TESS)	Percent (0-100)
Value of outcome score		
<i>If Type of functional outcome score = Yes (1)</i>	Calculated from date of definite surgery to date of functional outcome score	In months
Time to functional outcome		